Filtros de búsqueda

Lista de obras de

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

artículo científico publicado en 2002

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

artículo científico publicado en 2016

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

artículo científico publicado en 2019

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

artículo científico publicado en 2016

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

artículo científico publicado en 2010

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

scientific article published on 08 May 2018

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

artículo científico publicado en 2014

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2011

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

artículo científico publicado en 2010

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

artículo científico publicado en 2016

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

artículo científico publicado en 2018

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

artículo científico publicado en 2007

Antimyeloma activity of heat shock protein-90 inhibition.

artículo científico publicado en 2005

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

artículo científico publicado en 2009

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

artículo científico publicado en 2003

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

artículo científico publicado en 2008

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

artículo científico publicado en 2005

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

artículo científico publicado en 2009

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

artículo científico publicado en 2002

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy

artículo científico publicado en 2014

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

artículo científico publicado en 2012

Bortezomib in the front-line treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib in the management of multiple myeloma ⬇️

artículo científico publicado el 8 de septiembre de 2009

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

artículo científico publicado en 2009

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

artículo científico publicado en 2012

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

artículo científico publicado en 2009

Can thalidomide improve outcome in patients with multiple myeloma?

scientific article published on 01 November 2006

Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model.

artículo científico publicado en 2016

Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients

artículo científico publicado en 2011

Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles

artículo científico publicado en 2013

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

artículo científico publicado en 2008

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

artículo científico publicado en 2015

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

artículo científico publicado en 2007

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

artículo científico publicado en 2004

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

artículo científico publicado en 2012

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

artículo científico publicado en 2010

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

artículo científico publicado en 2011

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

artículo científico publicado en 2011

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

artículo científico publicado en 2011

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

artículo científico publicado en 2002

Deciphering the chronology of copy number alterations in Multiple Myeloma

artículo científico publicado en 2019

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

artículo científico publicado en 2015

Differential and limited expression of mutant alleles in multiple myeloma

artículo científico publicado en 2014

Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis

artículo científico publicado en 2007

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

artículo científico publicado en 2007

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

artículo científico publicado en 2014

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells ⬇️

artículo científico publicado el 1 de octubre de 2003

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

artículo científico publicado en 2010

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

artículo científico publicado en 2009

Emerging trends in the clinical use of bortezomib in multiple myeloma

artículo científico publicado en 2005

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study

artículo científico publicado en 2012

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

artículo científico publicado en 2015

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

artículo científico publicado en 2006

Functional cargo delivery into mouse and human fibroblasts using a versatile microfluidic device

artículo científico publicado en 2018

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

artículo científico publicado en 2009

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

scientific article published on 22 May 2020

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing

artículo científico publicado en 2018

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor

artículo científico publicado en 2005

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

artículo científico publicado en 2014

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

artículo científico publicado en 2018

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

artículo científico publicado en 2005

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

scientific article published on 08 June 2018

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

artículo científico publicado en 2003

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

artículo científico publicado en 2005

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

artículo científico publicado en 2010

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells

artículo científico publicado en 2013

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

artículo científico publicado en 2009

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2007

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

artículo científico publicado en 2018

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

artículo científico publicado en 2003

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

artículo científico publicado en 2009

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease

artículo científico publicado en 2013

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity

artículo científico publicado en 2013

Latest advances and current challenges in the treatment of multiple myeloma

artículo científico publicado en 2012

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

artículo científico publicado en 2015

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

artículo científico publicado el 15 de junio de 2010

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2010

Logic programming reveals alteration of key transcription factors in multiple myeloma

artículo científico publicado en 2017

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

artículo científico publicado en 2018

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.

artículo científico publicado en 2011

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

Management of myeloma-associated renal dysfunction in the era of novel therapies

artículo científico publicado en 2012

Management of relapsed and relapsed/refractory multiple myeloma

scientific article published on 01 October 2011

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings

artículo científico publicado en 2011

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

artículo científico publicado en 2004

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

artículo científico publicado en 2009

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

artículo científico publicado en 2011

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

artículo científico publicado en 2005

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

artículo científico publicado en 2002

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

artículo científico publicado en 2003

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

artículo científico publicado en 2002

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

artículo científico publicado en 2009

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

artículo científico publicado en 2007

NF-kappa B as a therapeutic target in multiple myeloma

artículo científico publicado en 2002

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

artículo científico publicado en 2003

New drugs for myeloma

artículo científico publicado en 2007

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

artículo científico publicado en 2014

Novel biologically based therapies for multiple myeloma

artículo científico publicado en 2002

Novel therapies in the treatment of multiple myeloma

artículo científico publicado en 2009

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

artículo científico publicado en 2003

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

artículo científico publicado en 2014

PAN-INTACT enables direct isolation of lineage-specific nuclei from fibrous tissues

artículo científico publicado en 2019

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

artículo científico publicado en 2010

Pathological crystallization of human immunoglobulins

artículo científico publicado en 2012

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

scientific article published on 15 May 2019

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

artículo científico publicado en 2011

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2006

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

artículo científico publicado en 2012

Phase transitions in human IgG solutions

artículo científico publicado en 2013

Phenotypically silent Cre recombination within the postnatal ventricular conduction system

artículo científico publicado en 2017

Prognostic significance of copy-number alterations in multiple myeloma

artículo científico publicado en 2009

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

artículo científico publicado en 2017

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

artículo científico publicado en 2004

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

artículo científico publicado en 2003

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

artículo científico publicado en 2002

Pyk2 promotes tumor progression in multiple myeloma

artículo científico publicado en 2014

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

artículo científico publicado en 2012

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2006

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

artículo científico publicado en 2015

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

artículo científico publicado en 2019

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

artículo científico publicado en 2009

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

artículo científico publicado en 2010

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

artículo científico publicado en 2008

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

artículo científico publicado en 2007

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

scientific article published on 01 October 2007

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

artículo científico publicado en 2012

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

artículo científico publicado en 2004

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

artículo científico publicado en 2006

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival

artículo científico publicado en 2016

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms

artículo científico publicado en 2011

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

artículo científico publicado en 2017

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

artículo científico publicado en 2002

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

artículo científico publicado en 2003

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease

scientific article published on 01 August 2018

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

artículo científico publicado en 2009

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

artículo científico publicado en 2012

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

artículo científico publicado en 2002

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

artículo científico publicado en 2007

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

artículo científico publicado en 2006

The shaping and functional consequences of the dosage effect landscape in multiple myeloma ⬇️

artículo científico publicado en 2013

The treatment of multiple myeloma patients not eligible for asct ⬇️

artículo científico publicado el 3 de mayo de 2010

The treatment of relapsed and refractory multiple myeloma

artículo científico publicado en 2007

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2002

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

artículo científico publicado en 2014

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

artículo científico publicado en 2003

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

artículo científico publicado en 2010

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

artículo científico publicado en 2013

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma ⬇️

artículo científico publicado el 28 de octubre de 2010

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients

scientific article published on 17 May 2013

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma

artículo científico publicado en 2003

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

artículo científico publicado en 2011

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

artículo científico publicado en 2004

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

artículo científico publicado en 2017

pouC Regulates Expression of bmp4 During Atrioventricular Canal Formation in Zebrafish

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda